MetaCap

Boston Scientific (BSX) vs DexCom (DXCM)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

DexCom (DXCM) has outperformed Boston Scientific (BSX) over the past year, gaining 31.7% versus a loss of 56.7%. Over five years, BSX leads with a +8.8% price change compared with -46.4% for DXCM. Boston Scientific is the larger company by market cap ($60.85 billion vs $29.58 billion), about 2.1 times the size.

On valuation, Boston Scientific trades at a lower forward P/E (13.4x vs 25.3x for DexCom). DexCom converts more of its revenue into profit, with a net margin of 17.9% versus 14.4%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BSX-56.67%DXCM+31.70%
+59%-2%-63%
Nov 21, 20251 yearNov 20, 2026
BSX+2.32%DXCM-50.52%
+173%+48%-77%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BSX versus DXCM key metrics
MetricBSXDXCM
Share price$41.98$79.32
Market cap$60.85B$29.58B
1-day change-2.35%-1.08%
YTD return-55.97%+19.51%
1-year return-56.67%+31.70%
5-year return+8.84%-46.40%
P/E ratio (TTM)17.7131.23
Forward P/E13.4125.30
EPS (TTM)$2.37$2.54
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$20.07B$4.66B
Revenue growth (YoY)+19.87%+15.60%
Net income (latest FY)$2.89B$836.30M
Gross margin69.01%60.10%
Operating margin18.00%19.56%
Net margin14.41%17.94%
52-week high$101.91$92.59
52-week low$39.57$56.72
Distance from 52-week high-58.81%-14.33%
Analyst consensusbuystrong_buy
Avg. price target upside+18.15%+24.28%
Average volume19.19M4.19M
Shares outstanding1.45B372.95M
Employees59,00011,000
SectorHealth CareHealth Care
IndustryMedical/Dental InstrumentsMedical/Dental Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Boston Scientific is about 2.1 times larger than DexCom by market value ($60.85B vs $29.58B).
  • DXCM has outperformed BSX by 88.4 percentage points over the past year.
  • DexCom trades at a higher earnings multiple (31.2x vs 17.7x trailing P/E).

About Boston Scientific

BSX stock →

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular.

Health Care · Medical/Dental Instruments · 59,000 employees

About DexCom

DXCM stock →

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application.

Health Care · Medical/Dental Instruments · 11,000 employees

BSX vs DXCM FAQ

Which is bigger, Boston Scientific or DexCom?

Boston Scientific (BSX) is larger, with a market capitalization of $60.85B compared with $29.58B for DexCom (DXCM).

Which stock has performed better over the past year, BSX or DXCM?

DXCM returned +31.70% over the past 12 months, compared with -56.67% for BSX (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, BSX or DXCM?

BSX has the lower trailing P/E at 17.7, versus 31.2 for DXCM. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Are Boston Scientific and DexCom in the same industry?

Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.

More comparisons